With the substantially enhanced understanding of AML pathogenesis, B cell lymphoma-2 (BCL-2), FMS-like tyrosine kinase 3 (FLT3), isocitrate dehydrogenases types 1 and 2 (IDH1/2) inhibitors, and other targeted therapeutic drugs have found utility in the clinical management of patients with AML and special genetic alterations [2–7]. This evidence concerns the gene BCL2 and acute myeloid leukemia.